DKFZ 25 records found  1 - 10nextend  jump to record: Search took 0.00 seconds. 
[DKFZ-2022-01948] Journal Article
; ; ; et al
Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers.
Germline variant evaluation in precision oncology opens new paths towards the identification of patients with genetic tumor risk syndromes and the exploration of therapeutic relevance. Here, we present the results of germline variant analysis and their clinical implications in a precision oncology study for patients with predominantly rare cancers.Matched tumor and control genome/exome and RNA sequencing was performed for 1,485 patients with rare cancers (79%) and/or young adults (77% younger than 51 years) in the NCT/DKTK MASTER trial, a German multicenter, prospective observational precision oncology study. [...]
[DKFZ-2022-01933] Journal Article
; ; ; et al
Bcl-xL as prognostic marker and potential therapeutic target in cholangiocarcinoma.
Liver international 42(12), 2855-2870 () [10.1111/liv.15392]  GO
Intrahepatic, perihilar and distal cholangiocarcinoma (iCCA, pCCA, dCCA) are highly malignant tumors with increasing mortality rates due to therapy resistances. Among the mechanisms mediating resistance, overexpression of anti-apoptotic Bcl-2 proteins (Bcl-2, Bcl-xL , Mcl-1) is particularly important. [...]
DBCoverage [DKFZ-2022-01722] Journal Article
; ; ; et al
Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity.
The benefit of molecularly-informed therapies in cancer of unknown primary (CUP) is unclear. Here, we use comprehensive molecular characterization by whole genome/exome, transcriptome and methylome analysis in 70 CUP patients to reveal substantial mutational heterogeneity with TP53, MUC16, KRAS, LRP1B and CSMD3 being the most frequently mutated known cancer-related genes. [...]
[DKFZ-2022-01386] Journal Article
; ; ; et al
Gene expression-based prediction of pazopanib efficacy in sarcoma.
The multi-receptor tyrosine kinase inhibitor pazopanib is approved for the treatment of advanced soft-tissue sarcoma and has also shown activity in other sarcoma subtypes. However, its clinical efficacy is highly variable, and no reliable predictors exist to select patients who are likely to benefit from this drug.We analysed the molecular profiles and clinical outcomes of patients with pazopanib-treated sarcoma enrolled in a prospective observational study by the German Cancer Consortium, DKTK MASTER, that employs whole-genome/exome sequencing and transcriptome sequencing to inform the care of young adults with advanced cancer across histology and patients with rare cancers.Among 109 patients with available whole-genome/exome sequencing data, there was no correlation between clinical parameters, specific genetic alterations or mutational signatures and clinical outcome. [...]
[DKFZ-2022-00658] Journal Article
; ; ; et al
Detecting drug resistance in pancreatic cancer organoids guides optimized chemotherapy treatment.
The journal of pathology 257(5), 607-619 () [10.1002/path.5906]  GO
Drug combination therapies for cancer treatment show high efficacy but often induce severe side effects resulting in dose or cycle number reduction. We investigated the impact of neoadjuvant chemotherapy (neoCTx) adaptions on treatment outcome in 59 patients with pancreatic ductal adenocarcinoma (PDAC). [...]
[DKFZ-2021-02503] Journal Article
; ; ; et al
The CIRCULATE Trial: Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation (AIO-KRK-0217).
Guidance regarding adjuvant treatment decisions in stage II colorectal cancer (CRC) remains uncertain due to lack of predictive clinical or molecular markers. Recently, postoperative circulating tumour (ct)DNA has been demonstrated to be a strong prognostic marker in early colon cancer.CIRCULATE enrols patients with stage II microsatellite stable CRC in Germany (AIO) and Austria (ABCSG). [...]
[DKFZ-2021-01304] Journal Article
; ; ; et al
Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers.
Cancer discovery 11(11), 2780-2795 () [10.1158/2159-8290.CD-21-0126]  GO
The clinical relevance of comprehensive molecular analysis in rare cancers is not established. We analyzed the molecular profiles and clinical outcomes of 1,310 patients (rare cancers, 75.5%) enrolled in a prospective observational study by the German Cancer Consortium that applies whole-genome/exome and RNA sequencing to inform the care of adults with incurable cancers. [...]

DKFZ : 25 records found   1 - 10nextend  jump to record:
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.